Bayer AG is joining forces with Acuitas Therapeutics, Inc
Bayer boosts its gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Inc.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1163 entries already.
Entries by Thomas Gabrielczyk
Cytovation ASA raises US$8m in Series A
/in News/by Thomas GabrielczykBergen-based Cytovation ASA has raised US$8m in a Series A extension round to push its cancer compound CyPep-1 into Phase II clinical testing. ,
eXmoor Pharma Ltd raises US$35m
/in News/by Thomas GabrielczykBristol-based eXmoor Pharma Ltd has completed a US$35m Series A financing to expand its cell and gene therapy manufacturing capabilities.
Stem cell gene transfer treats IL-1 immune diseases
/in News/by Thomas GabrielczykItalian researchers have successfully ameliorated several IL-1-based autoimmune disorders by gene therapy into transplantable hematopoietic stem cells of mice.
Glioma drug combo turns tumours hot
/in News/by Thomas GabrielczykAn anti-TNF-antibody-cytokine fusion combo with chemotherapy turns inoperable brain tumours hot in mice. A Phase I trial sponsored by Philogen SpA is underway.
AI predicts an enzymes substrate
/in News/by Thomas GabrielczykA new machine learning model can predict enzyme-substrate pairs, with an accuracy of over 90% and is ready to be used in pharmaceutical and industrial biotechnology.
LanzaTech and Plastipak produce greener PET
/in News/by Thomas GabrielczykCarbon-capture specialist LanzaTech Global and Plastipak Packaging Inc have produced the worlds first PET resin made from captured carbon emissions.
Roches meets endpoints in relapsing multiple sclerosis
/in News/by Thomas GabrielczykRoche’s brutons tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis.
Dualyx NV raises 40m in Series A financing
/in News/by Thomas GabrielczykBelgian T reg specialist Dualyx NV had raised 40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic.
Sanofi’s/Astazeneca’s anti-RSV antibody highly effective
/in News/by Thomas GabrielczykNHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial.